The popularity of Sildenafil initially sparked a surge for major pharmaceutical companies, but recent shifts present a complicated picture for shareholders. Lower-cost competitors are eating into earnings, and ongoing https://jessetxae034327.blog-a-story.com/22977892/sildenafil-and-the-pharmaceutical-industry-a-volatile-bet